Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances in Personalized Cancer Immunotherapies
November 15 2018 - 8:00AM
Event to be webcast live at 12 pm
ET
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical
company developing personalized cancer immunotherapies, announced
today that it will host a Key Opinion Leader (KOL) event focused on
the latest advances in personalized cancer immunotherapies in New
York City on Monday, November 26, 2018, at 12 p.m. ET.
The event will feature:
- Charles G. Drake, M.D., Ph.D., Co-Director, Cancer
Immunotherapy Programs at New York-Presbyterian/Columbia University
Medical Center and an influential leader in immunotherapy and
cancer research, who will discuss the latest advances in cancer
immunotherapies, with a focus on cancer vaccines and cell
therapies.
- Key members of the management team from Genocea, who will
provide an overview of the company's neoantigen discovery platform,
ATLAS™, and its lead clinical candidate GEN-009, a personalized
cancer vaccine candidate. GEN-009 uses the ATLAS platform to
optimize neoantigen identification and is currently being studied
in an ongoing Phase 1/2a clinical trial. Genocea will also discuss
the application of ATLAS to its investigational T cell therapy
program, GEN-011.
Dr. Drake is a physician-scientist whose work focuses on
understanding and fighting advanced-stage cancers with the immune
system. He is known for rapidly incorporating discoveries made in
the research lab into innovative clinical trials, including
anti-tumor vaccines and immunotherapies. Previously, Dr. Drake
served as the co-director of the Cancer Immunology Program at Johns
Hopkins School of Medicine and as co-director of the Prostate
Cancer Multi-Disciplinary Clinic. Earlier in his Hopkins career, he
was an associate professor in the Department of Oncology and an
assistant professor of medical oncology. He received a B.S. in
electrical engineering and an M.S. in biomedical engineering from
Rutgers University. He received a doctorate at the National Jewish
Center for Immunology and Respiratory Medicine at the University of
Colorado Health Sciences Center, and later earned his medical
degree from the University of Colorado as part of the MSTP program.
He completed his internship and residency in internal medicine at
the Osler Medical Service of Johns Hopkins Hospital, and his
medical oncology fellowship training in the Johns Hopkins
Department of Oncology. His research has been published in
prestigious journals such as the New England Journal of Medicine,
Cancer Research, the Journal of Clinical Investigation, and the
Journal of Clinical Oncology.
This event is intended for institutional investors, sell-side
analysts, investment bankers, and business development
professionals only. Please RSVP in advance if you plan to attend,
as space is limited. For those who are unable to attend in person,
a live webcast and replay of the event will be accessible here. If
you would like to ask a question during the live Q&A portion of
the event, please submit your request via email.
About Genocea Biosciences, Inc.Genocea's
mission is to help conquer cancer by designing and delivering
targeted vaccines and immunotherapies. While traditional
immunotherapy discovery methods have largely used predictive
methods to propose T cell targets, or antigens, Genocea has
developed ATLAS™, its proprietary technology platform, to identify
clinically relevant antigens of T cells based on actual human
immune responses. Genocea is using ATLAS to develop cancer vaccines
and immunotherapies. Genocea is currently studying the safety,
immunogenicity, and efficacy of its lead neoantigen cancer vaccine,
GEN-009, in a Phase 1/2a clinical trial. For more information,
please visit www.genocea.com.
Contact: Jennifer LaVin
617-715-6687jennifer.lavin@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Apr 2023 to Apr 2024